✦ LIBER ✦

Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model

✍ Scribed by Michael Patrick Lux; M. Hartmann; C. Jackisch; G. Raab; A. Schneeweiß; K. Possinger; J. Oyee; N. Harbeck

Publisher: Springer US
Year: 2009
Tongue: English
Weight: 849 KB
Volume: 117
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-008-0294-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost utility analysis of prophylactic pa

Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer

✍ G. Dranitsaris; Tom Hsu 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 73 KB

Assessing the cost effectiveness of adju

Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model

✍ Bruce E. Hillner; Thomas J. Smith; Christopher E. Desch 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 697 KB

Postmastectomy radiation therapy for lym

Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy : Analysis of the NCI Surveillance, Epidemiology, and End Results database

✍ James B. Yu; Lynn D. Wilson; Tina Dasgupta; William A. Castrucci; Joanne B. Weid 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

## Abstract ## BACKGROUND. The role of postmastectomy radiotherapy (PMRT) for lymph node‐negative locally advanced breast carcinoma (T3N0M0) after modified radical mastectomy (MRM) with regard to improvement in survival remains an area of controversy. ## METHODS. The 1973–2004 National Cancer In

Anastrozole is superior to tamoxifen as

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma : Results of two randomized trials designed for combined analysis

✍ Jacques Bonneterre; Aman Buzdar; Jean-Marc A. Nabholtz; John F. R. Robertson; Be 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 2 views

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB